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Background: microRNAs (miRNAs) play crucial roles in major biological processes and their deregulations are often
associated with human malignancies. As such, they represent appealing candidates as targets of innovative therapies.
Another interesting aspect of their biology is that they are present in various biological fluids where, advantageously,
they appear to be very stable. A plethora of studies have now reported their potential as biomarkers that can be used in
diagnosis, prognosis and/or theranostic issues. However, the application of circulating miRNAs in clinical practices still
requires the identification of highly efficient, robust and reproducible methods for their isolation from biological samples.
In that context, we performed an independent cross-comparison of three commercially available RNA extraction kits for
miRNAs isolation from human blood samples (Qiagen and Norgen kits as well as the new NucleoSpin miRNAs Plasma kit
from Macherey-Nagel). miRNAs were further profiled using the Taqman Low Density Array technology.
Results: We found that, although these 3 kits had equal performances in extracting miRNAs from peripheral blood
mononuclear cells, the Macherey-Nagel kit presented several advantages when isolating miRNAs from sera. Besides, our
results have indicated that, depending on the quantity of the biological samples used, the extraction procedure directly
impacted on the G/C composition of the miRNAs detected.
Conclusion: Overall, our study contributes to the definition of a reliable framework for profiling circulating miRNAs.Background
MicroRNAs (miRNAs) are a class of small noncoding
RNAs (typically 20–23 nt) that are important regulators
of gene expression at the post-transcriptional level. In
recent years, numerous studies have involved miRNA
disregulations in various diseases and the number of
miRNA publications is growing each year. To date, more
than a thousand miRNAs have been identified and
their presence in various body fluids (plasma, serum,
urine…) as well as their remarkable stability make them
excellent candidates for non-invasive biomarkers of vari-
ous human diseases [1]. For the development of miRNAs-
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unless otherwise stated.manipulation, miRNAs extraction, measurements and sta-
tistics need to be addressed [2-4]. For instance, several
studies have shown the importance of samples processing
[5,6]. Likewise, it was reported that hemolysis occurring
during blood collection has significant impact on the miR-
NAs content in plasma/serum [7-10]. The evaluation of
the quantity and quality of miRNAs isolated from bio-
logical samples is indeed a key step in miRNA profiling
studies. Although methods for miRNA extraction are usu-
ally similar to that used in the case of total RNAs (with
only slight modifications required to retain the small RNA
fraction), the sizes and relative abundance of ribosomal
RNAs cannot give information about the integrity of the
miRNA preparation. In addition, the quantification of
miRNA preparations can only be accurate in samples
where larger RNAs are not degraded as the degradation
products can compromise this quantification. Moreover,
the low concentration of RNAs present in body fluids
makes the estimation of miRNAs abundance particularlyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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filing is the qPCR efficiency that can be affected by minute
amounts of inhibiting compounds co-extracted with RNA
[12]. Besides, it has been reported that short RNAs with
low GC content may be selectively lost during extraction
from a small number of cells, depending on the extraction
methods [13]. It is thus crucial to compare different proto-
cols in order to identify the most reproducible and reliable
method. Several studies have indeed tackled this point,
revealing different performances between the commer-
cially available kits for the isolation of miRNAs [12,14-17].
Here, we broadened these analyses and compared, using
Taqman Low Density Arrays, miRNAs profiles of per-
ipheral blood mononuclear cells (PBMCs) and sera from
human healthy donors, obtained with three distinct
commercial kits: Qiagen, Norgen Biotek Corporation
and Macherey-Nagel. To the best of our knowledge the
Macherey-Nagel kit for plasma/serum has not been studied
before. In this paper, we showed that the quantity and the
quality of RNAs extracted from PBMCs with these three
kits did not significantly differ. This was in contrast to
miRNAs extraction from serum for which the Macherey-
Nagel kit presented several advantages. Besides, we found
that, irrespective of the kit used, increasing the quantity of
the starting biological materials (PBMC or serum) intro-
duced a bias in the isolation of miRNAs and favored the
extraction of G/C low miRNAs. We also bring evidence
that the optimal detection of miRNAs is not necessarily
obtained with the maximum quantity of total RNAs.
Methods
Samples isolation
Blood samples were obtained from ten blood donors who
underwent a brief medical examination (Etablissement
Français du Sang (EFS) Montpellier, France). These blood
samples were obtained in accordance to the ethical guide-
lines of the French Ministry of Health (Code de Santé
Publique Article L1131-1 and next). This study was
approved by the ethics committee of the EFS-Pyrénées-
Méditerranée (EFS-PM- Agreement: # 21/PLER/MTP/
CNR02/2013-007). All donors have given their written
consent for non-therapeutic use of their blood sample
donation. Whole blood samples from each donors were
collected in two Vacutainer tubes, one being EDTA coated
and the other non-EDTA coated. RNase-free protocols
were followed throughout all procedures. Sera were pre-
pared from blood collection tubes without anticoagulant
after centrifugation at 500 g for 10 minutes at room
temperature and inspected visually for any pink hue,
which is indicative of hemolysis [8], and then, immediately
frozen at −80°C. PBMCs were isolated, from EDTA tubes,
by Ficoll density gradient centrifugation (Sigma-Aldrich).
3×106 or 1×106 cells were mixed with lysis buffer ac-
cording to the manufacturers’ instructions for each RNAextraction kit, in order to achieve lysis and inactivate
endogenous RNAses. Lysates from PBMCs were frozen in
the lysis buffer at −80°C until next steps of RNA purifica-
tion. Experiments were performed with RNAs thawed
only once.
RNA extraction from PBMCs and serum samples
Total RNA was extracted from the PBMCs lysates (1×106
or 3×106 cells) using the miRNeasy mini kit (reference
217004, Qiagen, CA), the Total RNA Purification Kit
(product 17200, Norgen Biotek Corporation, Canada) and
the NucleoSpin miRNAs kit (reference 740971, Macherey-
Nagel, Düren, Germany) following the manufacturers’
protocols. Qiagen and Norgen kits require a Phenol/
Chloroform extraction step unlike the kits from Macherey-
Nagel. The Macherey-Nagel protocol allows isolating both
small and large RNAs in one or two fractions. Here, we
have chosen to extract total RNAs in one fraction. Total
RNAs were eluted in 30 μL nuclease-free water for Qiagen
kit or 50 μL for Norgen and for Macherey Nagel kits.
Total RNAs were extracted from thawed serum samples
using the miRNeasy mini kit (Qiagen, CA), the Plasma/
Serum Circulating RNA purification Kit (product 30000,
Norgen Biotek Corporation, Canada) and the NucleoSpin
miRNAs Plasma kit (reference 740981, Macherey-Nagel,
Düren, Germany). For both Qiagen and Macherey Nagel
kits, total RNAs were extracted from 300 μL or 600 μL of
serum and further eluted in 30 μL of nuclease-free water.
For the Norgen kit, total RNAs were extracted from 200 μL
of serum and eluted in 50 μL of nuclease-free water.
RNA quality
Total RNA concentration was expressed as micrograms or
nanograms RNA per million cells (for PBMCs) or per
milliliter of serum. The RNA concentration and quality
were first assessed using the NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, DE). PBMC sample
purity was estimated by measuring the ratio of spectro-
photometric absorbance (260 nm/280 nm). For a pure
RNA sample, this ratio should be comprised between 1.8
and 2 RNAs were further analyzed with the Bioanalyzer
2100 (Agilent Technologies, CA) using small RNA and
RNA 6000 Nano chips (Agilent, CA). The RNA Integrity
Number (RIN) obtained by the Nano 6000 kit for PBMCs
indicates the RNA quality of a sample (RIN values >8 are
commonly considered as high-quality RNA). Small RNA
(from 6 to 150 nt) and miRNAs (from 6 to 40 nt) concen-
trations as well [micro/small] RNA ratio were calculated
from the electropherogram of the Small RNA kit for
PBMC and sera.
TaqMan low-density arrays (TLDA) for miRNAs profiling
MicroRNA profiling of samples was performed using
TaqMan Array Human MicroRNA panels A and B (Life
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including 377 human miRNAs, three endogenous small
RNA controls (one of them being in quadruplicate), and
a negative control. 754 human miRNAs were quantified
in total. Reverse transcription and pre-amplification
were performed following the manufacturer’s instruc-
tions (Life technologies, CA). Briefly, 3 μL RNAs from
serum or 10 to 300 ng RNAs from PBMCs were reverse
transcribed using the Megaplex reverse transcription
(RT) reaction in a final volume of 7.5 μL using stem-
loop primers designed by Life Technologies. 2.5 μL of
this cDNA solution were used for a pre-amplification
step in a final volume of 25 μL then diluted four times
in distilled water DNase/RNase free (Life Technologies
Gibco). Nine μL of diluted pre-amplified product added
to 900 μL of total mix were used per TLDA card. Real time
quantitative PCR was performed with ViiA7 real-time PCR
system, and data were collected with the manufacturer’s
ViiA™ Software. Gene Expression Suite software (Applied
Biosystems, CA) was further used to process the array data.
Automatic thresholds were checked individually and
corrected when necessary.
Data analysis and statistical methods
Data processing and analysis were conducted using tools
from Microsoft Excel and Prism GraphPad V5.0d soft-
ware (GraphPad Software, CA). Comparisons of quantity
and quality data were performed using Mann Whitney
or Kruskal-Wallis test depending on the distribution of
the data. Only miRNAs with a cut-off of cycle threshold
(Ct) < 32 were considered in PBMCs while no cut-off
was applied in the case of serum since in this fluid, the
quantities of starting materials are much lower. Correla-
tions were calculated using the Spearman method. For
the Bland-Altman analysis, the association between the
difference and the average was evaluated by the coefficient
of correlation and tested by the non-zero correlation test.
Wilcoxon test was used to assess whether the median dif-
ference (bias) between the two conditions was significantly
different from 0 and the limits of agreement were defined
as median difference +/−1.96 SD. The thermodynamic
stability of miRNAs (kcal/mol) was calculated using
Quikfold from the DINAMelt web server (http://mfold.
rna.albany.edu/?q=DINAMelt/Quickfold) [18].
Results
Reproducibility of miRNAs expression profiles using
TLDA cards
The reproducibility of the miRNA expression profiling
using Taqman Low Density Array was first assessed by
comparing two separate qPCR experiments using the
same RT product obtained from total RNA isolated from
PBMCs with the recently available Macherey-Nagel (MN)
extraction kit. Seventy-one miRNAs were detected in thefirst experiment (d1) and 79 in the second (d2), with 63
miRNAs detected and 670 miRNAs not detected in both
experiments (i.e. 96.8% of reproducibility). The correlation
of the Ct values of miRNAs commonly detected was high
(r = 0.93) and a Bland-Altman plot showed small mean
difference (−0.19) with only one miRNA outside the limits
of agreement (Figure 1A). Secondly, two RT replicates
from the same RNA sample (150 ng) were compared. RT1
(d1) allowed detecting 71 miRNAs while RT2 detected 89
miRNAs. 63 miRNAs were detected in common while
663 miRNAs were undetectable (i.e. 95.9% of reproduci-
bility). The correlation coefficient was 0.90 and a Bland-
Altman plot displayed small mean difference (−0.04)
between Ct values with only five miRNA Ct values outside
the limits of agreement (Figure 1B).
The impact of increasing the amount of total RNAs
used for RT in TLDA miRNA profiles was also evaluated.
Three RTs were then performed using as starting material
of 10, 100 and 300 ng of total RNAs purified from 3×106
PBMCs with the MN kit (Figure 2). As expected, the Ct
values of the miRNAs detected in all 3 settings decreased
when the RNA quantity used for RT increased: mean Ct
difference of −2.51 between 10 and 100 and −1,07 be-
tween 100 and 300 (Figure 2A and B). An increase in the
number of detectable miRNAs was also logically observed
although not perfectly linear (28/93/120 miRNAs using
10, 100 and 300 ng of total RNA, respectively, Figure 2C).
The miRNAs detected with 10 ng of total RNAs were
detected with 100 ng and miRNAs detected with 100 ng
of total RNAs were also detected with 300 ng (Figure 2C).
Thus, the detection of miRNAs using the TLDA platform
is mostly influenced by the quantity of total RNAs used
for RT, not by the technology itself. Together our results
showed that TLDA is a reproducible method that is
therefore suitable to compare different RNA extraction
procedures.
Comparison of RNA quality and quantity
Macherey-Nagel, Qiagen, and Norgen extraction kits were
used to isolate total RNAs (including small and miRNAs)
from PBMCs (1×106 cells) and sera (300 μL for Qiagen
and MN or 200 μL for Norgen) from 10 healthy donors
(Table 1 and Additional file 1: Figure S1). First, we ob-
served that the quantity of RNA isolated from PBMCs with
the Norgen kit measured by Nanodrop (1.93 μg/1×106
cells, Table 1A) was higher than that obtained with MN
(p = 0.006 – Mann Whitney test) or Qiagen (p = 0.002 –
Mann Whitney test) while quantity measurements with
Agilent Nano 6000 chips yielded similar results. At the
quality level, ratio of absorbance at 260 nm and 280 nm
(A260/280) showed that the RNA purity obtained with
the MN kit was slightly better than that obtained with
Qiagen or Norgen kits (Table 1A, p = 0.0004 and p =
0.0025, respectively - Mann Whitney test). The RINs
Figure 1 Assessment of the TLDA reproducibility. The TLDA
reproducibility was assessed by testing, from one RNA sample, two
separate qPCR amplifications from A- the same RT and pre-amplification
product (RT1-d1 vs RT1-d2: Bland-Altman) and B- separate RT and
pre-amplification reactions (RT1 (d1) vs RT2: Bland-Altman). RT with
150 ng of RNA isolated from 3×106 cells with Macherey-Nagel kit. Only
miRNAs with Ct < 32 were considered.
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with the samples extracted using the Norgen kit (sd =
2.9). Agilent Small RNA chips did not indicate signifi-
cant difference in the quantities of small RNA andmiRNAs (Table 1A, micro/small RNA ratios of 14.4
(sd = 7.7), 13.6 (1.7) and 15.6 (19.4)% using MN, Qiagen
and Norgen extraction kits, respectively).
Second, the quantity and quality of RNAs extracted
from the serum samples were analyzed. No significant dif-
ference was observed in term of RNA quantities as mea-
sured by Nanodrop (Table 1B). Likewise, Agilent small
RNA chip analyses did not indicate significant difference
in small RNA and miRNAs quantities, although, for some
samples, the MN extraction kit yielded higher quantities
(Additional file 1: Figure S1 and Table 1B, mean miRNAs
concentration of 80, 22 and 11 ng/mL for MN, Qiagen
and Norgen extraction protocols, respectively). However
the quality of RNA obtained with the MN isolation kit
was higher (as indicated by the ratio miRNAs/smallRNA,
61.3%) compared to those obtained with the two other kits
(44.5% with Qiagen and 32.9%, p = 0.026 with Norgen-t-
test). Again, RIN variability obtained with the Norgen kit
was higher than that observed with the two other kits
(Table 1, compared sd = 0.52 vs. 0.11 (MN) and 1.4
(Qiagen)). As previously observed [4], the 260 nm/280 nm
ratio (<1.8) did not appear as a relevant parameter to
assess the miRNA quality in serum. Overall, the MN kit
seemed to yield better results compared to the two other
kits. However, the Norgen kit presented some inconstancy
in term of RNA quality extracted from both PBMCs and
sera. We therefore decided to pursue our comparison by
TLDA profiling focusing on the MN and Qiagen kits. It is
worth mentioning that the MN kit has never been exten-
sively tested.
Comparison of PBMCs and serum miRNAs profiles
Total RNAs were extracted from PBMCs (1×106 cells)
and sera (300 μL) of 3 distinct donors using the MN and
Qiagen kits. The miRNAs were profiled using a TLDA
platform (Figure 3). First, we evaluated the technical and
inter-individual variability, for each extraction kits, com-
paring the profiles of the biological triplicate (Additional
file 2: Figure S2). A low variability was observed in
PBMC profiles as no significant difference in Ct values
(Figure 3A) could be observed for detectable miRNAs
(p = 0.89 for MN and p = 0.49 for Qiagen extraction kit,
Kruskal-Wallis test) with a Ct mean differences between
samples inferior to 1 Ct (Additional file 2: Figure S2A).
72 (9.5%) miRNAs were detected (with Ct < 32) in MN-
extracted total RNAs while 107 (14.1%) miRNAs were
detected after Qiagen extraction (Figure 3A). 69 miR-
NAs were detected after extraction with both kits
(Figure 3A) with a good correlation of the Ct values
(Spearman ρ = 0.74, Figure 3B). The level of expression
of miRNAs isolated with Qiagen was slightly higher
compared to that observed with MN (Figure 3C), but
the Ct mean difference was not greater than 1 Ct. Only
three miRNAs had Ct values outside the limits of
Figure 2 Impact of the RNA quantity on miRNA TLDA profiles.
miRNA TLDA profiles were compared using three different RNA
quantities for RT (10, 100 and 300 ng), of the same RNA sample
extracted from 3×106 PBMCs by Macherey-Nagel. A- Bland-Altman
analysis: condition 100 ng of RNA for RT versus 10 ng. B- Bland-
Altman analysis: condition 300 ng of RNA for RT versus 100 ng.
C- Venn diagram with the detectable miRNAs. Only miRNAs with Ct < 32
were considered. The Pearson correlation coefficient is indicated.
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RNA extraction from PBMCs, we concluded that, miR-
Neasy mini kit from Qiagen and NucleoSpin miRNAs
kit from Macherey-Nagel, yielded comparable results.
In the case of serum samples, more variability in the
number of miRNAs detected by TLDA for each isolation
methods was observed within the biological triplicate
(Additional file 2: Figure S2B, Bland-Altman analysis,
mean differences ranging from 0.04 to 2.45). However,
no significant difference in the Ct values of commonly
detected miRNAs (Figure 3D) was observed (p = 0.33 for
MN and p = 0.85 for Qiagen extraction kit, Kruskal-
Wallis test). 83 miRNAs (11%) were amplified from
serum after MN extraction while 41 miRNAs (5.4%)
could be detected after Qiagen extraction (Figure 3D).
36 miRNAs were commonly detected with both kits
(Figure 3D). Quantities of miRNAs detected in serum
samples were very low, with median Ct values around 34
(Figure 3D). Nonetheless, the miRNAs expression pro-
files evaluated with RNA isolated from both extraction
kits correlated (ρ = 0.71, p < 0.0001, Figure 3E). The
amounts of miRNAs detected with both kits were simi-
lar, with a mean difference of −0.5 (Figure 3F). Only two
miRNAs had Ct values outside the limits of agreement
of the Bland-Altman test (Figure 3F). Overall, our results
indicated that miRNAs profiles from serum samples
could be highly variable. These results confirmed that ro-
bust statistical tests should be performed when evaluating
the potential of circulating miRNAs as diagnostic/prog-
nostic markers [19]. Moreover, we provide evidence that
the NucleoSpin miRNAs Plasma kit from Macherey-Nagel
is more efficient in extracting miRNAs from serum than
the Qiagen miRNeasy mini kit as it allowed detecting
twice as many miRNAs.
Impact of the quantity of the starting biological material
on miRNAs profiles
Then, the performances of the Macherey-Nagel NucleoS-
pin miRNAs Plasma kit were further examined. First , to
evaluate whether increasing the volume of serum could
improve miRNAs detection and profiling, the number of
detectable miRNAs and their Ct values were compared, in
biological duplicate, after RNA extraction from 300 or
600 μL of serum. Nanodrop concentration after elution
indicated 13 ng/μL (from 600 μL of serum) and 7 ng/μL
Table 1 Assessment of quantity and quality of RNA isolated
A Macherey Nagel Qiagen Norgen
PBMC n 8 10 10
Nanodrop Total RNA: Mean quantity (ug/1×106 cells or ml serum) (SD) 1.03 (0.22) 0.97 (0.14) 1.93 (0.69)
Ratio OD (260 nm/280 nm) (SD) 2.04 (0.07) 1.75 (0.06) 1.91 (0.07)
Agilent Nano 6000 Chip Total RNA: Mean Quantity (ug/1×106 cells or ml serum) (SD) 1.19 (0.33) 0.96 (0.30) 0.98 (0.50)
RIN mean (SD) 8.84 (0.34) 8.73 (0.41) 7.33 (2.93)
B Macherey Nagel Qiagen Norgen
Serum n 10 10 10
Nanodrop Total RNA: Mean quantity (ug/1×106 cells or ml serum) (SD) 0.91 (0.46) 0.89 (0.40) 0.99 (0.34)
Ratio OD (260 nm/280 nm) (SD) 1.24 (0.11) 1.40 (0.13) 1.27 (0.52)
The quantity and quality of RNA isolated from (A) PBMCs and (B) serum using three RNA extraction kits (Macherey-Nagel, Qiagen, Norgen) were evaluated by
Nanodrop, Agilent nano 6000 (PBMCs only) and Agilent small RNA chips.
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the total number of detectable miRNAs by TLDA was
slightly increased: 57 vs 38 miRNAs and 26 miRNAs were
detected with both volumes. A Bland-Altman plot of their
Ct values showed that miRNAs extracted from 600 μL of
serum were detected with lower Ct values compared to
300 μL with mean difference of −1.10 (Figure 4A). We
then computed the correlation between this difference in
Ct values and the GC content of the miRNAs (ρ = 0.42,
p = 0.04, Figure 4B). Strikingly, this calculation indi-
cated that the sample volumes could impact on the de-
tection of specific miRNAs depending on their G/C
composition, in accordance to previous results [13].
To test if this bias in the GC content was also observed
with PMBC-isolated RNAs, the miRNAs profiles obtained
after RNA extraction from 1×106 or 3×106 cells were
compared using the same amount of total RNA for the
RT step (130 ng). Experiments were also performed in du-
plicate and the mean Ct values of miRNAs detected in
both cases was calculated. As expected, the quantity of
RNA isolated from 3×106 cells was higher than that ob-
tained from 1×106 cells (94 vs. 41 ng/μL respectively).
RNA qualities were comparable as assessed by Agilent
(nano 6000 and small RNA chips). Using an equal amount
of RNA, the total number of detected miRNAs was higher
after extraction from 3×106 cells compared to 1×106 cells
(63 and 35 miRNAs, respectively, 33 miRNAs detected in
both settings). A Bland-Altman plot of their Ct values
showed that the miRNAs detected using RNA isolated
from 3×106 cells had lower Ct values, with a mean differ-
ence in Ct of −1.46 compared to 1×106 cells extraction
(Figure 5A), reminiscent of the results obtained with sera.
We calculated the correlation between the difference in Ct
values and the GC content (ρ = 0.42, p = 0.02, Figure 5B).
As observed in the case of serum samples, miRNAs whose
detection is sensitive to the quantity of the starting mater-
ial used for MN extraction seemed to exhibit low GC con-
tent. Of note, no bias was observed in the GC content
(Figure 5C, ρ = −0.08, p = 0.47) when different quantitiesof total RNA (300 and 100 ng) were compared for the
RT step.
To investigate whether these observations were limited
to the MN kit or whether RNA extraction with the Qiagen
kit could introduce similar bias. Total RNAs were
extracted from 1×106 or 3×106 PBMCs using the Qiagen
miRNeasy mini kit and further profiled with TLDA cards.
Similar to the results obtained after MN extraction, a
Bland-Altman plot of the Ct values of the 61 miRNAs de-
tected in both settings showed that the mean difference in
Ct values of miRNAs detected in 3×106 cells vs 1×106 cells
equaled −1 (Additional file 3: Figure S3A). This difference
tends to correlate with the GC content (ρ = 0.29, p =
0.02, Additional file 3: Figure S3B although to a lesser
extent, than observed in the case of MN extraction. To-
gether these results confirmed at a genome-scale level and
for two different miRNAs extraction kits previous observa-
tions made with Trizol RNA extraction procedures from
human cell lines [13]. Kim et al. also reported that miR-
NAs extraction could be biased by RNA structures [13].
The existence of such bias was evaluated in our settings
but any significant correlation was observed between
the thermodynamic stability of miRNAs, as assessed by
Quikfold, and the difference in Ct values (Additional
file 4: Figure S4). Hence, this suggests that the extraction
procedures used here did not introduce biases related to
miRNA structures (Additional file 4: Figure S4).
Discussion
Circulating miRNAs have recently emerged as non-
invasive biomarkers of diverse pathologies. For a routine
clinical use, technical standardization in the preparation
of the samples and profiling methods are therefore im-
portant. The first factor that can affect the reproduci-
bility of results is the quality of isolated RNA from
human blood samples. In this study, we performed an
independent cross-comparison of three extraction pro-
cedures for miRNA isolation from human blood samples
using Macherey-Nagel, Qiagen, and Norgen kits. In order
Figure 3 Comparison of miRNAs expression profiles from human PBMCs and serum. Human PBMCs (1×106 cells) and serum (300 μL)
samples were extracted by Macherey-Nagel (MN) and Qiagen (Q) kits. A- Number of miRNAs detected from PBMCs RNA samples using TLDA
cards. B- Correlation analysis from PBMCs samples. C- Bland-Altman analysis MN versus Q from PBMCs. D- Number of miRNAs detected from
serum RNA samples using TLDA cards. E- Correlation analysis from serum samples. F- Bland-Altman analysis MN versus Q from serum. TLDA data
were obtained from biological triplicate for each extraction kits. Analysis using mean Ct values of triplicate. Only miRNAs with Ct < 32 were
considered for PBMCs. No Ct cut-off was applied for serum miRNAs.
Monleau et al. BMC Genomics 2014, 15:395 Page 7 of 11
http://www.biomedcentral.com/1471-2164/15/395
Figure 4 Assessment of bias in RNA isolation using Macherey-Nagel kit from 300 or 600 μL serum. A- Bland-Altman analysis 600 versus
300 μL of serum. B- Plot of the difference in Ct values of the two conditions (x-axis) and the GC content of the miRNAs detected in these two
settings (y-axis). The Pearson correlation coefficient is indicated. The GC content corresponds to the percentage of GC in the sequence of mature
miRNAs. TLDA datas from biological duplicate. Analysis using mean CT values of common miRNAs, without Ct cut-off.
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to modify the manufacturer’s protocols. The originality of
our study is that we compared miRNA profiles based on a
TLDA platform.
The miRNAs were further profiled using the genome-
scale Taqman Low Density Array technology. We indeed
verified that this technology was reproducible in term of
qPCR (ρ = 0.93) and RT (ρ = 0.90), with good agreement
in Bland-Altman plots. Similarly, Chen et al. tested
TLDA reproducibility on miRNAs detected in two dif-
ferent RTs and two different qPCRs using rodent cards
and RNAs isolated from proliferating murine myoblast
cells with Trizol method (from 500 ng RNA without
pre-amplification and from 150 ng with or without pre-
amplification) [20]. The comparison of the two replicates
showed a strong correlation (ρ =0.978 for experiment
using 500 ng RNA and ρ = 0.985 and ρ = 0.990 using
150 ng without and with pre-amplification, respectively).
Wang and colleagues observed a correlation coefficient
of 0.812 in the TLDA results using the same sample (hu-
man osterosarcoma xenografts, RNA isolated by Trizol,
no pre-amplification) [21]. Jensen et al. tested specificity,
reproducibility and sensibility of TLDA and miRCURY
platforms using both synthetic miRNAs and plasma
samples isolated by miRNeasy kit from Qiagen [22]. Con-
cerning TLDA platform (protocol with pre-amplification)
and plasma sample, reproducibility was assessed from one
sample using two separate RT reactions and the products
of each reaction were used in separate qPCR amplifica-
tions. The comparison of every duplicate pairs demon-
strated a median correlation coefficient of 0.96 (cutoff
Ct < 30) [22].
Given that, the 3 kits were first compared for their
performances in extracting miRNAs from PBMCs in
term of RNA quantity and quality. However, the new
Macherey-Nagel kit was more efficient in extracting
miRNAs from sera. Another advantage of this kit is that,unlike the Qiagen and Norgen extraction kits, it does
not require the cumbersome phenol/chloroform step.
Several previous reports have compared miRNAs extrac-
tion kits. Notably, Kroh et al. have tested variations on
two extraction kits from plasma and serum samples:
Ambion mirVana PARIS (with addition of an additional
organic extraction step), and the Qiagen miRNeasy kit
(with a modified protocol to use 10 volumes of Qiazol
reagent per volume of plasma or serum). They showed
that, although both protocols have proven effectiveness,
the Qiagen protocol appears to produce 2–3-fold greater
RNA yield [12]. Likewise, Li and colleagues evaluated
the performances of the miRNeasy kit (Qiagen, CA), the
miRVana PARIS kit (Ambion, TX) and the total RNA
isolation kit (Norgen Biotek, Canada) [14]. They con-
cluded that RNAs isolated by the Qiagen or Ambion kits
had better quality (in terms of % of miRNAs in small
RNA fraction) than those extracted with the Norgen kit.
In term of RNA quantity, the concentrations of miRNAs
in serum were 49 pg/μL, 29 pg/μL and 12 pg/μL from
the Qiagen, Ambion and Norgen kits, respectively. Here,
we obtained comparable amount of RNAs ranging from
11 (Norgen) to 80 (Macherey-Nagel) pg/μL.
Using TLDA profiling, we showed that the Macherey-
Nagel kit allowed the detection of more miRNAs than the
Qiagen kit (83 vs 41) in serum. Previous reports have
shown a higher number of miRNAs detectable from
serum samples by TLDA (around 170 miRNAs with RNA
isolation with the Qiagen miRNeasy or the Ambion miR-
Vana miRNA kits) [23-26]. However, in these studies,
TLDA experiments were performed on serum pool of 10
to 20 samples.
One striking finding in our study is that, comparing
two different volumes of serum or PBMCs numbers
used to extract miRNAs with the Macherey-Nagel or
the Qiagen kits, we showed that the quantity of the bio-
logical samples directly impacted the GC content of the
Figure 5 Assessment of bias in RNA isolation from PBMCs.
Assessment of bias in RNA isolation from PBMCs using the
Macherey-Nagel (MN) kit, comparison of extraction from 3×106 and
1×106 cells with a same amount of RNA for RT (130 ng). A- Bland-
Altman analysis 3×106 versus 1x106 cells. B- Plot of the difference in
Ct values of the two conditions (x-axis) and the GC content of miR-
NAs detected in these two settings (y-axis). C- Plot of the difference
in Ct values of the conditions 300 vs 100 ng (x-axis) and the GC
content of the miRNAs detected in these two settings (y-axis). The
Pearson correlation coefficient is indicated. TLDA datas from biological
duplicate. Analysis using mean CT values of common miRNAs. Only
miRNAs with Ct < 32 were considered.
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results obtained by Kim et al., who showed that specific
miRNAs can be lost during RNA extraction using TRI-
zol protocol (not with the Ambion miRVana miRNAs
kit) depending on their GC content and their thermo-
dynamic stability [13]. These results were obtained
using cells from different density culture as starting
RNA materials and miRNAs were detected by northern
blotting. With these findings, Kim et al. hypothesized
that small RNAs could require larger RNA carriers
[13]. However, our results do not support this hypoth-
esis as we found similar GC content bias in serum sam-
ples (Figure 4B) wherein no large RNAs was detected
(Additional file 1: Figure S1B). We rather postulate that
the presence of additional compounds (proteins and/
or lipids that are associated with miRNAs, [27,28] and
whose quantity increase with starting material) can affect
the nature of the miRNAs extracted. These compounds
could further be lost during the RNA purification proced-
ure implying that their concentrations would not show in-
trinsic linear relationship between cell input and total
RNA. However, their presence in the initial steps of the
purification could truly influence the GC composition of
the purified RNAs. Together with that of Kim et al., our
study support the use of identical quantities/volumes for
starting materials to compare miRNA profiles.
Conclusion
Overall, our results emphasize the importance of compar-
ing miRNAs extraction protocols in order to standardize
RNA isolation and to compare miRNAs profiles. In fact,
numerous high-profile preclinical studies have already
yielded conflicting data and outcomes due to differences
in methodologies [29,30]. There is therefore an urgent
need of protocol standardization to enhance the future
prospects of extracellular miRNAs in diagnosis, progno-
sis, and surveillance, even in therapeutic application.
These types of study are all the more warranted, as the
assays based on the extracellular miRNAs expression
signatures prove useful as a noninvasive test to guide a
physician’s clinical decision on comprehensive manage-
ment of patients.
Monleau et al. BMC Genomics 2014, 15:395 Page 10 of 11
http://www.biomedcentral.com/1471-2164/15/395Additional files
Additional file 1: Figure S1. Comparison of the quality of total RNA
isolated with three kits. A- Examples of Agilent nano 6000 and small RNA
profiles obtained from RNA isolated from PBMCs samples. B- Examples of
Agilent small RNA profiles obtained from RNA isolated from serum
samples. Fluorescence intensity of RNA fractions at different sizes and
associated gel electrophoresis.
Additional file 2: Figure S2. Bland-Altman analysis of miRNAs Ct values
between the three RNA samples isolated by Macherey-Nagel (MN) and
Qiagen extraction kits. A: From PBMCs samples (1×106 cells). Only miRNAs
with Ct < 32 were considered. B: From serum (300 μL) samples, no cut-off.
Additional file 3: Figure S3. Assessment of bias in RNA isolation from
PBMCs samples using the Qiagen kit, comparison of extraction from
3×106 and 1×106 cells with the same amount of RNA for RT (110 ng).
A- Bland-Altman analysis 3×106 versus 1×106 cells. B- Plot of the difference
in Ct values of the two conditions (x-axis) and the GC content of miRNAs
detected in these two settings (y-axis). The Pearson correlation coefficient is
indicated. TLDA datas from biological duplicate. Analysis using mean CT
values of common miRNAs. Only miRNAs with Ct < 32 were considered.
Additional file 4: Figure S4. Assessment of bias in RNA isolation from
serum and PBMCs using the Macherey-Nagel (MN) kit: difference in Ct
values of the two conditions in function of the thermodynamic stability
of miRNAs. A- PBMCs: extraction from 3×106 and 1×106 cells but same
amount of RNA for RT (130 ng). B- Serum: extraction from 600 versus
300 μL. TLDA datas from biological duplicate. Analysis using mean CT
values of common miRNAs. Only miRNAs with Ct < 32 were considered
for PBMCs. No Ct cut-off was applied for serum miRNAs.
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